Insiders who reported open-market trades in the last 12 months at the companies Ryan Cohlhepp files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Ryan Cohlhepp is a corporate insider, tracked as President, COO & Interim CEO, Director of Bicara Therapeutics Inc. (BCAX). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Ryan Cohlhepp submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Ryan Cohlhepp been buying or selling stock?
Recorded transactions: 0 open-market purchases and 29 open-market sales ($4.60M) across all tracked filings.
Ryan Cohlhepp is President, COO & Interim CEO, Director of Bicara Therapeutics Inc. (BCAX). 15 SEC Form 4 filings on record going back to 2025, most recently on 10 September 2026. Most recent open-market trade: sold $81K of BCAX on 10 September 2026. Lifetime open-market sales: $4.60M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Ryan Cohlhepp.
InsiderAlpha's records for Ryan Cohlhepp go back to 2025: 15 primary Form 4 filings, an average of 7.5 per year. 55 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
